Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-086 pembrolizumab monotherapy in metastatic triple-negative breast cancer
2015-000294-13Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2015
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in triple-negative breast cancer (TNBC) (2 cohorts), sponsored by Merck & Co. Primary endpoint: Overall response rate. Started Apr 2015; status: completed.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2015-000294-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000294-13.